SecBot SecBot
424B5 ·Filed Jun 25, 2026

TSHA

Taysha Gene Therapies, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001193125-26-282846
Notable filing: 424B5
Actionable Insight ▼ Bearish

Traders should monitor post-offering price action for TSHA given the 13.6% discount to prior close, anticipate near-term selling pressure as the market absorbs ~32.5M new shares. The 60-day lockup on insiders/executives limits insider selling, but underwriters may release shares early. Key catalysts: REVEAL pivotal trial 6-month interim analysis (topline data expected H1 2027) and FDA Type C meeting follow-up. Pro forma cash of ~$464M removes near-term financing risk and funds BLA preparation.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.34
T+0 close · Jun 25, 2026 · via day close
Latest settled
−20.50%
T+60 · $5.04
Vs SPY
−26.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 26 $6.34entry
  2. T+1 · 5mo ago +6.15%α +4.50% · $6.73
  3. T+5 · 4mo ago +3.00%α +0.83% · $6.53
  4. T+20 · 4mo ago −8.04%α −9.30% · $5.83
  5. T+60 · 8w ago −20.50%α −26.61% · $5.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Taysha Gene Therapies is raising approximately $187.4 million ($215.6 million if underwriters' option is exercised) through the sale of 32.5M shares of common stock and pre-funded warrants at $6.00 per share, representing a 13.6% discount to the $6.94 prior closing price. Net proceeds combined with existing $276.6M cash will fund TSHA-102 BLA preparation/commercial launch and pipeline development, extending runway into H2 2028. The offering creates immediate 79% dilution ($4.75/share) for new investors.

Key Facts

  • Offering of 32,500,001 shares of common stock at $6.00/share, a 13.6% discount to the prior close of $6.94
  • Pre-funded warrants for up to 833,333 additional shares at $5.999 per warrant (exercise price $0.001)
  • Net proceeds estimated at $187.4M (or $215.6M with underwriter option exercise)
  • Immediate dilution of $4.75 per share for new investors (79% of offering price)
  • Post-offering shares outstanding increase to 319,776,886 from 287,276,885 (11.3% increase)
  • Cash and equivalents of $276.6M as of March 31, 2026; pro forma cash ~$464M
  • Underwriters have 30-day option to purchase 5,000,000 additional shares

Financial Impact

Gross proceeds of $200M; net proceeds ~$187.4M after underwriting discounts and expenses. Immediate dilution of $4.75/share (79%) to new investors at $6.00 offering price. Post-offering cash runway extended to H2 2028.

dilutioncash runwayshares outstanding

Risk Factors

  • Significant immediate dilution (79%) may pressure stock price
  • Pre-funded warrant exercises could add further dilution
  • Clinical-stage biotech with no approved products, regulatory/clinical risk remains high
  • Underwriters may release lock-up shares early, increasing supply
  • Cash burn rate for clinical/CMC activities could accelerate if trials expand

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-282846
Document: d95601dexfilingfees.htm0001193125-26-282846
Document: 0001193125-26-282846-index-headers.html0001193125-26-282846
Document: 0001193125-26-282846-index.html0001193125-26-282846
Document: 0001193125-26-282846.txt0001193125-26-282846

Track record

14 reports on TSHA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
  3. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
  4. Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
  5. Jun 25, 202620w ago 424B5 Bearish 6/10 Viewing Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
  6. Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
  7. Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
  8. May 6, 202627w ago 8-K Neutral 5/10 No price data
  9. May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
  10. Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 25, 2026